Lumida
/DNA
⌘K
Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc

DNA
$6.75USD-0.44%-0.03 today

MARKET CAP

454.5M

P/E (TTM)

FWD P/E

DAY RANGE

$7 – $7

52W RANGE

$5
$18

AI Summary

Stalk
StalkMedium

DNA remains in a Stage 2 advancing phase with a bullish medium-term bias evidenced by a clear sequence of higher highs and higher lows. However, the long-term trend is down, anchoring structural polarity. In the short-term, price is extended above rising EMAs and RSI is overbought, reducing the attractiveness of immediate entries. Patient pullbacks into the 9/20 EMA band offer structurally favorable engagement, supported by low transition risk and lack of exhaustion.

  • Secured MIT and Caltech agreements to scale autonomous lab network
  • Partnered with Acies Bio to commercialize high-performance Aspergillus niger strains
  • Q2 revenue fell 48% YoY to $20M, signaling demand challenges
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$313.8M$477.7M$251.5M$227.0M$170.2M
YoY %+52.2%-47.4%-9.7%-25.1%
P / Sales36.0x5.6x12.9x2.2x2.7x
EV / Sales32.7x4.5x11.4x2.7x5.3x
Gross Profit, Adj.$184.1M$273.5M$197.4M$182.5M$123.2M
YoY %+48.5%-27.8%-7.6%-32.5%
Margin %58.7%57.3%78.5%80.4%72.4%
EV / Gross Profit55.7x7.8x14.5x3.3x7.3x
EBITDA, Adj.$-1.8B$-2.2B$-697.7M$-424.7M$-244.9M
YoY %-19.5%+67.6%+39.1%+42.3%
Margin %-573.9%-450.6%-277.5%-187.1%-143.9%
EV / EBITDA-5.7x-1.0x-4.1x-1.4x-3.7x
EBIT$-1.8B$-2.2B$-864.4M$-559.8M$-315.3M
YoY %-18.5%+60.2%+35.2%+43.7%
Margin %-583.2%-454.1%-343.8%-246.5%-185.3%
EV / EBIT-5.6x-1.0x-3.3x-1.1x-2.9x
Net Income$-1.8B$-2.1B$-892.9M$-547.0M$-312.8M
YoY %-15.0%+57.6%+38.7%+42.8%
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (GAAP)-$55.60-$50.20-$18.37-$10.54-$5.64
YoY %+9.7%+63.4%+42.6%+46.5%